BridgeBio Oncology Therapeutics (BBOT) Total Current Liabilities (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Total Current Liabilities of $43.3 million for Q1 2026, up 23.46% sequentially from $35.0 million in Q4 2025, and up 2212.45% YoY from $1.9 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Total Current Liabilities (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Total Current Liabilities for 4 years, with the latest figure at $43.3 million in Q1 2026.
- Quarterly Total Current Liabilities rose 2212.45% year-over-year to $43.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.3 million (up 2212.45% YoY) and the FY2025 annual result came in at $35.0 million, up 78.96% from the prior year.
- Total Current Liabilities improved to $43.3 million in Q1 2026 per BBOT's latest filing, from $35.0 million in the prior quarter.
- Over five years, Total Current Liabilities peaked at $43.3 million in Q1 2026 and troughed at $23333.0 in Q1 2024.
- A 4-year average of $13.9 million and a median of $2.2 million in 2025 frame the typical range for Total Current Liabilities.
- The widest YoY moves for Total Current Liabilities: up 28088.49% in 2025, down 78.96% in 2025.
- Over 4 years, Total Current Liabilities stood at $396463.0 in 2023, then jumped by 4838.67% to $19.6 million in 2024, then surged by 78.96% to $35.0 million in 2025, then climbed by 23.46% to $43.3 million in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $43.3 million, $35.0 million, and $35.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 51.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.63 Mn |
| Mar 31, 2026 | 43.26 Mn |
| Dec 31, 2025 | 35.04 Mn |
| Sep 30, 2025 | 35.71 Mn |
| Jun 30, 2025 | 2.63 Mn |
| Mar 31, 2025 | 1.87 Mn |
| Dec 31, 2024 | 19.58 Mn |
| Sep 30, 2024 | 126,690.00 |
| Jun 30, 2024 | 79,141.00 |
| Mar 31, 2024 | 23,333.00 |
| Dec 31, 2023 | 396,463.00 |